RGNX Shareholders May Pursue Class Action Against REGENXBIO Inc. for Misleading Information

RGNX Shareholder Alert: A Call to Action for REGENXBIO Investors

Recently, shareholders of REGENXBIO Inc. (NASDAQ: RGNX) have been alerted by The Gross Law Firm regarding their potential involvement in a class action lawsuit. This initiative comes as a response to the company's alleged dissemination of misleading information and material omissions regarding their gene therapy product, RGX-111.

The class action period spans from February 9, 2022, to January 27, 2026. Investors who purchased shares during this timeframe are urged to step forward as potential lead plaintiffs. It’s important to highlight that while being appointed as a lead plaintiff can enhance one’s position, it is not a prerequisite to participate in any eventual recovery.

Background on REGENXBIO and RGX-111

REGENXBIO is focused on developing and commercializing innovative gene therapies, with RGX-111 being targeted for the treatment of severe Mucopolysaccharidosis Type I, commonly referred to as Hurler syndrome. Prior to the concerning announcements, the company had maintained a positive outlook on RGX-111's potential, citing promising results from ongoing clinical trials. The defendants in the lawsuit allegedly made positive assertions on the therapy’s effectiveness without disclosing significant risks and adverse findings.

On January 28, 2026, the situation took a potentially detrimental turn when REGENXBIO disclosed that the FDA had placed a clinical hold on RGX-111. This followed the discovery of an intraventricular CNS tumor in a trial participant, raising serious questions about the safety and efficacy of the treatment.

Impact of Recent Developments

Following the announcement, there was a significant drop in REGENXBIO's stock value. Shares, which had closed at $13.41 a day earlier, fell to $11.01, reflecting a massive decline of 17.8%. This sudden drop is alarming for shareholders who had relied on the company’s communications, emphasizing the importance of transparency and accountability in the financial markets.

Next Steps for Shareholders

Shareholders who believe they have suffered losses due to these issues are encouraged to register their participation in this class action. The Gross Law Firm has made the registration process straightforward, emphasizing that there is no cost or obligation involved. Interested parties can access the registration link here.
The deadline to apply to be a lead plaintiff is April 14, 2026. By registering, shareholders will also gain access to a portfolio monitoring software, which will keep them updated on the lawsuit's progress.

Why Choose The Gross Law Firm?

The Gross Law Firm has earned a reputation as a leading class action law firm committed to protecting the rights of investors facing corporate malpractice. Their mission is to seek justice for shareholders impacted by false disclosures and unethical practices from companies.

In conclusion, shareholders of REGENXBIO Inc. who purchased shares during the specified period should take heed of these developments and consider their options moving forward. With the pressing deadline for registering as a lead plaintiff, prompt action is encouraged to safeguard their interests.